• Aiyin Chen, Thomas N Hwang, Laura T Phan, Timothy J McCulley, and Michael K Yoon.
• Department of Ophthalmology, University of California-San Francisco, San Francisco, California, USA.
• Middle East Afr J Ophthalmol. 2012 Oct 1; 19 (4): 432-5.

AbstractRituximab, a monoclonal antibody to the B cell marker CD20, is becoming increasingly popular in the treatment of various orbital disorders. In this university-based interventional case series, we describe two patients with bilateral orbital and extra-orbital reactive lymphoid hyperplasia (RLH) treated with rituximab. Initially both had favorable responses; but roughly a year later recurrent disease necessitated maintenance therapy in both cases. Both again responded to additional courses of rituximab. Although recalcitrant disease may persist after treatment, rituxmab may play a role in the management of RLH with widespread involvement.

26 keywords...

hide…